<?xml version="1.0" encoding="UTF-8"?>
<ref id="B153-biomedicines-08-00060">
 <label>153.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Annels</surname>
    <given-names>N.E.</given-names>
   </name>
   <name>
    <surname>Mansfield</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Arif</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Ballesteros-Merino</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Simpson</surname>
    <given-names>G.R.</given-names>
   </name>
   <name>
    <surname>Denyer</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Sandhu</surname>
    <given-names>S.S.</given-names>
   </name>
   <name>
    <surname>Melcher</surname>
    <given-names>A.A.</given-names>
   </name>
   <name>
    <surname>Harrington</surname>
    <given-names>K.J.</given-names>
   </name>
   <name>
    <surname>Davies</surname>
    <given-names>B.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Phase I trial of an ICAM-1-targeted immunotherapeutic-Coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer</article-title>
  <source>Clin. Cancer Res.</source>
  <year>2019</year>
  <volume>25</volume>
  <fpage>5818</fpage>
  <lpage>5831</lpage>
  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-4022</pub-id>
  <pub-id pub-id-type="pmid">31273010</pub-id>
 </element-citation>
</ref>
